Table 10.
Antimicrobial resistance in Salmonella Typhimurium from humans per country in 2015
| Country | Ampicillin | Azithromycin | Cefotaxime | Ceftazidime | Chloramphenicol | Ciprofloxacinb | Colistin | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N | % Res | N | % Res | N | % Res | N | % Res | N | % Res | N | % Res | N | % Res | |
| Austria | 203 | 44.3 | – | – | 203 | 1 | 203 | 1 | 203 | 10.8 | 203 | 5.4 | – | – |
| Cyprus | 25 | 76.0 | – | – | 6 | NA | 21 | 0 | – | – | – | – | 6 | NA |
| Denmark | 64 | 32.8 | 64 | 0.0 | 64 | 3.1 | 64 | 3.1 | 64 | 12.5 | 64 | 3.1 | 64 | 1.6 |
| Estonia | 12 | 25.0 | – | – | 12 | 0 | 12 | 0 | 12 | 8.3 | 12 | 0 | 3 | NA |
| Finland | 80 | 10.0 | – | – | 80 | 0.0 | – | – | 80 | 1.3 | 80 | 5.0 | – | – |
| France | 141 | 73.0 | 141 | 0 | 141 | 0 | 141 | 0.0 | 140 | 57.1 | 141 | 9.2 | 2 | NA |
| Germanya | 509 | 71.1 | – | – | 509 | 1.2 | 509 | 1.0 | 509 | 9.0 | 509 | 0.2 | – | – |
| Greece | 63 | 19.0 | – | – | 63 | 0 | 62 | 0 | 63 | 3.2 | 63 | 0 | – | – |
| Hungarya | 256 | 43.8 | – | – | 256 | 0.8 | 256 | 2.7 | 256 | 23.4 | 254 | 11.0 | – | – |
| Ireland | 46 | 41.3 | 46 | 2.2 | 46 | 0 | 46 | 0 | 46 | 21.7 | 46 | 4.3 | – | – |
| Italy | 11 | 81.8 | – | – | 11 | 0 | 11 | 0 | 11 | 54.5 | 11 | 9.1 | – | – |
| Latviaa | 8 | NA | – | – | – | – | – | – | – | – | 4 | NA | – | – |
| Lithuaniaa | 122 | 71.3 | – | – | 79 | 1.3 | 57 | 0 | 57 | 5.3 | 98 | 4.1 | – | – |
| Luxembourg | 17 | 23.5 | – | – | 17 | 5.9 | 17 | 0 | 17 | 17.6 | 17 | 11.8 | – | – |
| Maltaa | 18 | 77.8 | – | – | – | – | – | – | – | – | 18 | 33.3 | – | – |
| Netherlands | 184 | 44.6 | 184 | 0 | 184 | 2.7 | 184 | 0 | 184 | 9.8 | 184 | 7.1 | 184 | 1.6 |
| Portugal | 23 | 87.0 | – | – | 23 | 0 | 23 | 0 | 23 | 39.1 | 23 | 34.8 | – | – |
| Romania | 43 | 65.1 | – | – | 43 | 0 | 43 | 0 | 43 | 2.3 | 43 | 0 | – | – |
| Slovakiaa | 50 | 42.0 | – | – | 21 | 0 | – | – | – | – | 25 | 0 | – | – |
| Sloveniaa | 48 | 60.4 | – | – | 48 | 0 | 48 | 0 | 48 | 39.6 | 48 | 41.7 | – | – |
| Spaina | 226 | 73.5 | – | – | 226 | 0.9 | 226 | 0 | 225 | 29.8 | 226 | 12.4 | – | – |
| United Kingdoma | 113 | 54.9 | – | – | 109 | 3.7 | – | – | 107 | 18.7 | 106 | 0 | – | – |
| Total (22 MSs) | 2,262 | 56.3 | 435 | 0.2 | 2,136 | 1.1 | 1,923 | 0.8 | 2,088 | 18.0 | 2,178 | 6.6 | 259 | 1.5 |
| Icelanda | 4 | NA | – | – | – | – | – | – | – | – | 4 | NA | – | – |
| Norway | 76 | 10.5 | 18 | 0 | 76 | 0 | 76 | 0 | 18 | 22.2 | 76 | 2.6 | – | – |
| Country | Gentamicin | Nalidixic acid | Sulfamethoxazolec | Tetracycline | Tigecycline | Trimethoprim | Co‐trimoxazole | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N | % Res | N | % Res | N | % Res | N | % Res | N | % Res | N | % Res | N | % Res | |
| Austria | 203 | 1.0 | 203 | 5.4 | 203 | 42.9 | 203 | 43.3 | 203 | 0 | 203 | 2.0 | – | – |
| Cyprus | 14 | 35.7 | – | – | – | – | 6 | NA | 5 | NA | – | – | – | – |
| Denmark | 64 | 0 | 64 | 3.1 | 64 | 35.9 | 64 | 20.3 | 64 | 4.7 | 64 | 10.9 | – | – |
| Estonia | 12 | 8.3 | 5 | NA | 12 | 41.7 | 12 | 25.0 | – | – | 12 | 8.3 | – | – |
| Finland | 80 | 0 | 80 | 5.0 | – | – | 80 | 5.0 | – | – | 80 | 2.5 | – | – |
| France | 141 | 5.7 | 140 | 8.6 | 141 | 74.5 | 141 | 76.6 | 141 | 1.4 | 141 | 40.4 | 130 | 53.1 |
| Germanya | 509 | 0.6 | 508 | 3.1 | – | – | 508 | 63.4 | – | – | – | – | 508 | 11.0 |
| Greece | 63 | 0 | 63 | 0 | 63 | 38.1 | 63 | 36.5 | – | – | 63 | 7.9 | – | – |
| Hungarya | 256 | 1.6 | – | – | – | – | 19 | 52.6 | – | – | 256 | 3.5 | 256 | 6.3 |
| Ireland | 46 | 2.2 | 46 | 2.2 | 46 | 43.5 | 46 | 43.5 | 46 | 0 | 46 | 8.7 | – | – |
| Italy | 11 | 0 | 11 | 0 | 11 | 27.3 | 11 | 18.2 | – | – | 11 | 9.1 | 11 | 9.1 |
| Latviaa | – | – | – | – | – | – | – | – | – | – | – | – | 8 | NA |
| Lithuaniaa | 45 | 4.4 | 44 | 9.1 | – | – | 44 | 75.0 | – | – | 45 | 8.9 | 112 | 7.1 |
| Luxembourg | 17 | 0 | – | – | 17 | 58.8 | 17 | 58.8 | – | – | 17 | 0 | 17 | 5.9 |
| Maltaa | – | – | – | – | – | – | – | – | – | – | – | – | 18 | 27.8 |
| Netherlands | 184 | 1.1 | 184 | 6.0 | 184 | 36.4 | 184 | 33.2 | 184 | 2.2 | 184 | 14.1 | – | – |
| Portugal | 23 | 4.3 | 23 | 34.8 | 23 | 65.2 | 23 | 73.9 | – | – | 23 | 4.3 | – | – |
| Romania | 43 | 0 | 43 | 0 | 43 | 39.5 | 43 | 34.9 | – | – | 43 | 7.0 | 43 | 2.3 |
| Slovakiaa | – | – | – | – | – | – | 29 | 31.0 | – | – | – | – | 21 | 9.5 |
| Sloveniaa | 48 | 0 | – | – | 47 | 63.8 | 48 | 56.3 | – | – | 48 | 6.3 | 48 | 6.3 |
| Spaina | 226 | 0.9 | 226 | 21.2 | 226 | 67.3 | 226 | 59.3 | – | – | 226 | 10.6 | – | – |
| United Kingdoma | 104 | 1.0 | 108 | 7.4 | 103 | 60.2 | 103 | 65.0 | – | – | 129 | 9.3 | 25 | 4.0 |
| Total (22 MSs) | 2,094 | 1.6 | 1,746 | 7.2 | 1,187 | 52.4 | 1,870 | 51.9 | 643 | 1.4 | 1,591 | 10.2 | 1,197 | 13.7 |
| Icelanda | – | – | – | – | – | – | – | – | – | – | – | – | 4 | NA |
| Norway | 76 | 1.3 | 18 | 11.1 | – | – | 18 | 50.0 | – | – | – | – | 76 | 1.3 |
All Salmonella isolates tested were susceptible to meropenem.
N: number of isolates tested; % Res: percentage of microbiologically resistant isolates (either interpreted as non‐wild type by ECOFFs or clinically non‐susceptible by combining resistant and intermediate categories); –: no data reported; NA: not applicable – if less than 10 isolates were tested, the percentage of resistance was not calculated; MS: Member State.
Data interpreted with clinical breakpoints.
In several countries, ciprofloxacin has been replaced by pefloxacin for screening for fluoroquinolone resistance with disk diffusion, as recommended by EUCAST.
Combined data on the class of sulfonamides and the substance sulfamethoxazole within this group.